Siolta Therapeutics products

The Power to Prevent: Allergic diseases, including atopic dermatitis, food allergy, allergic asthma, and allergic rhinitis, have a common underlying inflammatory cascade and often occur in a sequential order referred to as “the atopic march.” STMC-103H, also known as adored: allergic disease onset prevention study, is Siolta’s proof of concept study aimed at stopping allergic disease before it’s starts by targeting early intervention of infants at high risk for developing allergic diseases.

Necrotizing enterocolitis is a serious inflammatory disease of the bowel and the most common single cause of sepsis and death in preterm infants. NEC occurs primarily in infants born before 32 weeks gestation, with overall incidence inversely proportional to gestational age. Several additional risk factors for NEC, including initiation of enteral feeding, antibiotic treatment, and acid suppression treatment, are key factors influencing the development of the preterm infant gut microbiome.

Bacterial vaginosis is one of the most common women’s health conditions, impacting up to 50% of women globally.  Bacterial vaginosis is associated with disruptions to the protective community of bacteria in the vaginal tract and the colonization by opportunistic microbes.   Standard of care treatments using antibiotics can be effective at treating bacterial vaginosis by reducing microbial burden, however these approaches fail to address the critical need to establish a stable and protective microbiota for long-term vaginal health and prevention of disease recurrence.

Siolta’s Precision Symbiotics Platform enables rapid LBP development. A platform focused on translating microbiome science into novel therapeutics for a healthier world. Siolta’s patient-centric platform leverages our internal expertise in microbiome data analysis, machine learning, anaerobic microbiology, and translational studies to rationally design and optimize multi-strain live biotherapeutics for the prevention and treatment of diseases of high unmet medical need. Top therapeutic candidates are manufactured in-house under cGMP conditions ensuring pharmaceutical-grade purity, potency, and consistency. Siolta’s streamlined internal capabilities and expertise rapidly drives lead candidates from discovery to proof-of-concept clinical studies.